Helicobacter Rescue Therapy With Vonorazon and Amoxicillin Dual Therapy Versus Bismuth-containing Quadruple Therapy

PHASE4CompletedINTERVENTIONAL
Enrollment

688

Participants

Timeline

Start Date

June 6, 2023

Primary Completion Date

May 30, 2024

Study Completion Date

August 30, 2024

Conditions
Gastritis Dyspepsia Helicobacter Pylori Infection Gastric Cancer Peptic Ulcer
Interventions
DRUG

Vonoprazan

Vonoprazan and amoxicillin dual therapy:given for 14 days at a dose of vonoprazan 20mg 1 tablet BID plus amoxicillin 500 mg 2 capsules TID

DRUG

amoxicillin

Vonoprazan and amoxicillin dual therapy:given for 14 days at a dose of vonoprazan 20mg 1 tablet BID plus amoxicillin 500 mg 2 capsules TID

DRUG

Bismuth

Bismuth-containing quadruple therapy: given for 14 days at a dose of bismuth 110 mg 2 capsules BID plus esomeprazole 20 mg 2 tablets BID#tetracycline 250mg 2 capsules TID and furazolidone 100mg 1 tablets BID

DRUG

Esomeprazole

Bismuth-containing quadruple therapy: given for 14 days at a dose of esomeprazole 20mg 2 tablets BID plus bismuth 110 mg 2 capsules BID#tetracycline 250mg 2 capsules TID and furazolidone 100mg 1 tablets BID

DRUG

Tetracycline

Bismuth-containing quadruple therapy:given for 14 days at a dose of tetracycline 250mg 2 capsules TID plus furazolidone 100mg 1 tablets BID#esomeprazole 20 mg 2 tablets BID and bismuth 110 mg 2 capsules BID

DRUG

Furazolidone

Bismuth-containing quadruple therapy:given for 14 days at a dose of furazolidone 100mg 1 tablets BID plus tetracycline 250mg 2 capsules TID#esomeprazole 20 mg 2 tablets BID and bismuth 110 mg 2 capsules BID

Trial Locations (2)

710032

Xijing Hosipital of Digestive Disease, Xi'an

Unknown

Xijing Hosipital of Digestive Disease, Xi’an

All Listed Sponsors
lead

Yongquan Shi

OTHER

NCT06168084 - Helicobacter Rescue Therapy With Vonorazon and Amoxicillin Dual Therapy Versus Bismuth-containing Quadruple Therapy | Biotech Hunter | Biotech Hunter